2.55Open2.55Pre Close0 Volume18 Open Interest185.00Strike Price0.00Turnover83.83%IV25.50%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry2.55Extrinsic Value100Contract SizeAmericanOptions Type-0.0888Delta0.0029Gamma96.04Leverage Ratio-0.1615Theta-0.0167Rho-8.53Eff Leverage0.1080Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet